Status:
COMPLETED
Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer
Lead Sponsor:
University of Chicago
Conditions:
Tumor
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Patients with metastatic cancer are generally treated with chemotherapy, which has improved median survival compared to best supportive care. Despite this, patients continue to have persistent disease...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed diagnosis of cancer (including epithelial carcinoma, sarcoma, and melanoma)
- Age 18 years and older
- Life expectancy of \> 3 months
- Patients with AJCC (6th edition, 2002) stage IV cancer with distant metastases and without pleural or pericardial effusion at diagnosis and before start of study
- Patients with 1-5 sites of maximum tumor dimension (for each individual site) of ≤ 10 cm or \< 500 cc volume and amenable to radiation therapy as seen on standard imaging
- Unidimensionally measurable disease (based on RECIST) is desirable but not strictly required
- Brain metastases must have been treated prior to enrollment on study, preferably with stereotactic radiosurgery
- ECOG performance status ≤ 2 or Karnofsky Performance Status ≥ 60%
- No prior radiation therapy to currently involved tumor sites
- Room air saturation \> 90%
- Hemoglobin \> 9.0 g/dl
- ANC \>=1,500/microliter
- Platelets \>=100,000/microliter
- Total bilirubin within institutional limits
- Albumin \> 2.9 g/dl
- Alkaline phosphatase \< 2.5x upper limit of normal
- AST and ALT \< 2.5 x upper limit of normal
- Ability to understand and willingness to sign a written informed consent document
Exclusion
- Uncontrolled intercurrent illness
- Patients with clinically significant pulmonary dysfunction, cardiomyopathy, or any history of clinically significant CHF are excluded. Exclusion of patients with active coronary heart disease will be at the discretion of the attending physician
- Patients with significant atelectasis such that CT definition of gross tumor volume is difficult to determine
- Pregnancy or breast feeding
- Patients must have no uncontrolled active infection other than that not curable with treatment of their cancer.
- Patients may not be receiving any other investigational drugs during RT
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2018
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT01215500
Start Date
January 1 2005
End Date
March 1 2018
Last Update
September 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chicago
Chicago, Illinois, United States, 60637